Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.

Sana Biotechnology, a US-based developer of stem cell medicines based on research at multiple universities, closed its inaugural funding round at $700m on Tuesday with commitments from investors including conglomerate Alphabet. F-Prime Capital, a unit of financial services group Fidelity, also took part in the round, as did Arch Venture Partners, Flagship Pioneering, Canada Pension…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.